Hollis Eden Pharmaceuticals Inc. (HEPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (118)	11/30/2000 1:11:47 PM
From: Jim Oravetz	Read Replies (1) of 138

SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) said preclinical results show that HE2100 inhibited human breast tumor cell proliferation in both estrogen receptor positive and estrogen receptor negative cells. Investigational drug candidate HE2100 is a second-generation immune modulator licensed to Hollis-Eden. In a press release Thursday, the company said the preclinical study was designed to measure the effects of HE2100 on tumor cell proliferation in-vitro over six days from two different human breast cancer cell lines compared with a negative vehicle control. The study showed that, in-vitro, HE2100 inhibits human breast cancer tumor cell growth whether or not estrogen receptor was present and was more effective when estrogen hormone was added. The company said the data is encouraging because most breast cancer therapies on the market act on the estrogen receptor, and the experiment showed that HE2100 inhibited breast cancer tumor growth independent of the estrogen receptor. Results of the study were published in the current issue of Cancer Detection and Prevention.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next